Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-03-18
DOI
10.1111/dom.14696
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease
- (2021) Alfred K. Cheung et al. KIDNEY INTERNATIONAL
- Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
- (2021) Ralph A. DeFronzo et al. Nature Reviews Nephrology
- Cardiovascular Disease in Chronic Kidney Disease
- (2021) Joachim Jankowski et al. CIRCULATION
- Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage
- (2021) Peter Kolkhof et al. AMERICAN JOURNAL OF NEPHROLOGY
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
- (2021) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trends in Diabetes Treatment and Control in U.S. Adults, 1999–2018
- (2021) Michael Fang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Importance of trial design when investigating cardiorenal outcomes in patients with CKD and T2D: Focus on CREDENCE and FIDELIO-DKD
- (2021) Rajiv Agarwal et al. AMERICAN HEART JOURNAL
- Novel non‐steroidal mineralocorticoid receptor antagonists in cardiorenal disease
- (2021) Ulrich Kintscher et al. BRITISH JOURNAL OF PHARMACOLOGY
- Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
- (2021) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial
- (2021) Rajiv Agarwal et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
- (2021) Naveed Sattar et al. Lancet Diabetes & Endocrinology
- CKD Awareness Among US Adults by Future Risk of Kidney Failure
- (2020) Chi D. Chu et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
- (2020) Darren K. McGuire et al. JAMA Cardiology
- Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes
- (2020) Gerasimos Filippatos et al. CIRCULATION
- Effects of Canagliflozin in Patients with Baseline eGFR
- (2020) George Bakris et al. Clinical Journal of the American Society of Nephrology
- 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis
- (2019) Jonatan Barrera-Chimal et al. KIDNEY INTERNATIONAL
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction
- (2018) Marianne Lachaux et al. DIABETES OBESITY & METABOLISM
- Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic ActivityNovelty and Significance
- (2018) Jana Grune et al. HYPERTENSION
- Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury–Mediated Chronic Kidney DiseaseNovelty and Significance
- (2017) Lionel Lattenist et al. HYPERTENSION
- 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
- (2017) Peter Kolkhof et al. JOURNAL OF ENDOCRINOLOGY
- A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
- (2016) Gerasimos Filippatos et al. EUROPEAN HEART JOURNAL
- Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014
- (2016) Maryam Afkarian et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
- (2016) Ralph A. DeFronzo et al. Nature Reviews Nephrology
- Aldosterone Induces Renal Fibrosis and Inflammatory M1-Macrophage Subtype via Mineralocorticoid Receptor in Rats
- (2016) Beatriz Martín-Fernández et al. PLoS One
- CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats
- (2015) Kiyoshi Arai et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
- (2015) George L. Bakris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1
- (2015) Larbi Amazit et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Cause of Death in Patients with Reduced Kidney Function
- (2015) S. Thompson et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
- (2015) Matthew R. Weir et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium Zirconium Cyclosilicate in Hyperkalemia
- (2015) David K. Packham et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diabetic kidney disease
- (2015) Merlin C. Thomas et al. Nature Reviews Disease Primers
- Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
- (2014) Peter Kolkhof et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- The Synergistic Relationship Between Estimated GFR and Microalbuminuria in Predicting Long-term Progression to ESRD or Death in Patients With Diabetes: Results From the Kidney Early Evaluation Program (KEEP)
- (2013) Amit P. Amin et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Determinants and Changes Associated with Aldosterone Breakthrough after Angiotensin II Receptor Blockade in Patients with Type 2 Diabetes with Overt Nephropathy
- (2013) O. Moranne et al. Clinical Journal of the American Society of Nephrology
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
- (2013) Bertram Pitt et al. EUROPEAN HEART JOURNAL
- Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
- (2013) Linda F. Fried et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vascular Actions of Aldosterone
- (2012) Marie Briet et al. JOURNAL OF VASCULAR RESEARCH
- Aldosterone Antagonists in Monotherapy Are Protective against Streptozotocin-Induced Diabetic Nephropathy in Rats
- (2012) Nora F. Banki et al. PLoS One
- Deletion of Cardiomyocyte Mineralocorticoid Receptor Ameliorates Adverse Remodeling After Myocardial Infarction
- (2011) Daniela Fraccarollo et al. CIRCULATION
- Renin-Angiotensin-Aldosterone System in Diabetes and Hypertension
- (2011) Willa A. Hsueh et al. Journal of Clinical Hypertension
- Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease
- (2011) M. Lian et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans
- (2010) Thomas Thum et al. EUROPEAN HEART JOURNAL
- A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule
- (2010) Jérôme Fagart et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice
- (2010) Michael G. Usher et al. JOURNAL OF CLINICAL INVESTIGATION
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
- (2010) The Emerging Risk Factors Collaboration LANCET
- The RAAS in the pathogenesis and treatment of diabetic nephropathy
- (2010) Piero Ruggenenti et al. Nature Reviews Nephrology
- Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
- (2010) Faiez Zannad et al. NEW ENGLAND JOURNAL OF MEDICINE
- International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes
- (2009) DIABETES CARE
- Deletion of Mineralocorticoid Receptors From Macrophages Protects Against Deoxycorticosterone/Salt-Induced Cardiac Fibrosis and Increased Blood Pressure
- (2009) Amanda J. Rickard et al. HYPERTENSION
- Aldosterone induces myofibroblastic transdifferentiation and collagen gene expression through the Rho-kinase dependent signaling pathway in rat mesangial cells
- (2008) Suwarni Diah et al. EXPERIMENTAL CELL RESEARCH
- Mineralocorticoid Receptor Antagonism Attenuates Cardiac Hypertrophy and Prevents Oxidative Stress in Uremic Rats
- (2008) Luis Michea et al. HYPERTENSION
- Body Mass Index Predicts Plasma Aldosterone Concentrations in Overweight-Obese Primary Hypertensive Patients
- (2008) Gian Paolo Rossi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started